• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Waters Prices Offering of Senior Notes

    3/18/26 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email

    MILFORD, Mass., March 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) (the "Company" or "Waters") today announced that it has priced an offering (the "Offering") of $3.5 billion aggregate principal amount of the following senior notes issued by its subsidiary, Augusta SpinCo Corporation ("Augusta"):

    • $650 million aggregate principal amount of 4.321% Senior Notes due 2027 at the issue price of 100.000% of their principal amount;
    • $600 million aggregate principal amount of 4.398% Senior Notes due 2029 at the issue price of 100.000% of their principal amount;
    • $750 million aggregate principal amount of 4.656% Senior Notes due 2031 at the issue price of 100.000% of their principal amount;
    • $750 million aggregate principal amount of 4.945% Senior Notes due 2033 at the issue price of 100.000% of their principal amount; and
    • $750 million aggregate principal amount of 5.245% Senior Notes due 2036 at the issue price of 100.000% of their principal amount (collectively, the "Notes").

    The Offering is expected to close on or about March 23, 2026, subject to the satisfaction of customary closing conditions.

    The Notes will be fully and unconditionally guaranteed by Waters and certain of its direct and indirect subsidiaries. Waters intends to use the net proceeds from the Offering, together with cash on hand, to repay $3.5 billion of indebtedness outstanding under the delayed draw term loan incurred by Augusta in February 2026.

    Barclays Capital Inc. is acting as global coordinator and Citigroup Global Markets Inc., J.P. Morgan Securities LLC, BofA Securities, Inc. and HSBC Securities (USA) Inc. are acting as active bookrunners for the Offering.

    The Offering is being made pursuant to an effective shelf registration statement on Form S-3ASR (File No. 333-294314) filed by Waters with the U.S. Securities and Exchange Commission (the "SEC") under the Securities Act of 1933, as amended. The Offering will be made by means of a prospectus supplement and accompanying prospectus only. A copy of the preliminary prospectus supplement and accompanying prospectus are available on the SEC's website at www.sec.gov. Alternatively, any underwriter or any dealer participating in the Offering will arrange to send you the preliminary prospectus supplement (or, if available, the prospectus supplement) and the accompanying prospectus if you request them by contacting: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by toll-free phone: (888) 603-5847 or by email: [email protected]; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected], or by calling (800) 831-9146; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected] and [email protected]; BofA Securities, Inc., 201 North Tryon Street, NC1-022-02-25, Charlotte, NC 28255-0001, Attention: Prospectus Department, at [email protected] or by telephone at 1-800-294-1322; or HSBC Securities (USA) Inc., 66 Hudson Boulevard, New York, NY 10001, Attention: Debt Capital Markets or by calling (866) 811-8049.

    This press release shall not constitute an offer to sell or a solicitation of an offer to purchase the Notes or any other securities. No offer, solicitation or sale will be made in any jurisdiction in which such an offer, solicitation or sale would be unlawful.

    About Waters Corporation

    Waters Corporation (NYSE:WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of approximately 16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide.

    Forward-Looking Statements

    This release contains "forward-looking" statements regarding future results and events, including statements regarding the Offering. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "will," "feels", "believes", "anticipates", "plans", "expects", "intends", "suggests", "appears", "estimates", "projects" and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. Our actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, our ability to complete the Offering, risks and uncertainties relating to general market conditions which might affect the Offering and other risk factors detailed from time to time in Waters' reports filed with the SEC. Such factors and others that are discussed more fully in the sections entitled "Forward-Looking Statements" and "Risk Factors" of Waters' annual report on Form 10-K for the year ended December 31, 2025 as filed with the SEC, which discussions are incorporated by reference in this release, as updated by Waters' subsequent filings with the SEC. The forward-looking statements included in this release represent Waters' estimates or views as of the date of this release and should not be relied upon as representing Waters' estimates or views as of any date subsequent to the date of this release. Except as required by law, Waters does not assume any obligation to update any forward-looking statements.

    Contacts

    Molly Gluck 

    Head of External Communications

    Waters Corporation

    508.498.9732

    [email protected] 

    Caspar Tudor 

    Head of Investor Relations

    Waters Corporation

    508.482.3448

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/waters-prices-offering-of-senior-notes-302716776.html

    SOURCE Waters Corporation

    Get the next $WAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    2/10/2026$360.00In-line
    Evercore ISI
    2/10/2026$425.00Buy
    Citigroup
    2/10/2026$400.00Overweight
    Barclays
    1/6/2026$440.00Buy
    Guggenheim
    1/5/2026Outperform
    William Blair
    12/10/2025$480.00Peer Perform → Outperform
    Wolfe Research
    12/2/2025$423.00Equal-Weight
    Morgan Stanley
    10/8/2025$390.00Buy
    Rothschild & Co Redburn
    More analyst ratings

    $WAT
    SEC Filings

    View All

    SEC Form FWP filed by Waters Corporation

    FWP - WATERS CORP /DE/ (0001000697) (Subject)

    3/17/26 5:27:04 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 8-K filed by Waters Corporation

    8-K - WATERS CORP /DE/ (0001000697) (Filer)

    3/16/26 8:44:25 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form S-8 filed by Waters Corporation

    S-8 - WATERS CORP /DE/ (0001000697) (Filer)

    2/23/26 4:16:33 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Waters Prices Offering of Senior Notes

    MILFORD, Mass., March 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) (the "Company" or "Waters") today announced that it has priced an offering (the "Offering") of $3.5 billion aggregate principal amount of the following senior notes issued by its subsidiary, Augusta SpinCo Corporation ("Augusta"): $650 million aggregate principal amount of 4.321% Senior Notes due 2027 at the issue price of 100.000% of their principal amount;$600 million aggregate principal amount of 4.398% Senior Notes due 2029 at the issue price of 100.000% of their principal amount;$750 million aggregate principal amount of 4.656% Senior Notes due 2031 at the issue price of 100.000% of their principal amount;$750

    3/18/26 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Flagship ARES‑G3 Rheometer Sets New Benchmark for Data Quality at Breakthrough Speed

    News Summary:Reduces standard testing times by 80%.1Delivers an industry-leading 25,000 data points per second, detecting transient material behaviors previously invisible to measurement. 2Operates with fewer calibrations and superior atmosphere and temperature control. 3SAN ANTONIO, Texas and MILFORD, Mass., March 9, 2026 /CNW/ -- Pittcon 2026 Conference + Exposition -- Waters Corporation (NYSE: WAT) today launched the ARES-G3™ Rheometer, part of the TA Instruments product line. This next-generation rheometer delivers industry-leading speed paired with best-in-class data to accelerate materials research and product development. Capturing up to 25,000 data points per second (10x more than it

    3/9/26 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation to Present at the TD Cowen Health Care Conference

    MILFORD, Mass., Feb. 23, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen Health Care Conference on Monday, March 2nd, 2026, at 11:10 AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days.About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatic

    2/23/26 4:45:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on Waters with a new price target

    Evercore ISI resumed coverage of Waters with a rating of In-line and set a new price target of $360.00

    2/10/26 8:10:12 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Barclays resumed coverage on Waters with a new price target

    Barclays resumed coverage of Waters with a rating of Overweight and set a new price target of $400.00

    2/10/26 8:03:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Citigroup resumed coverage on Waters with a new price target

    Citigroup resumed coverage of Waters with a rating of Buy and set a new price target of $425.00

    2/10/26 8:03:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fearon Richard H bought $306,340 worth of shares (1,000 units at $306.34), increasing direct ownership by 43% to 3,302 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    3/10/26 4:21:34 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    5/29/24 11:23:35 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fearon Richard H bought $306,340 worth of shares (1,000 units at $306.34), increasing direct ownership by 43% to 3,302 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    3/10/26 4:21:34 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Batra Udit covered exercise/tax liability with 3,417 shares, decreasing direct ownership by 9% to 33,140 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    3/3/26 4:24:48 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SVP & Chief Financial Officer Chaubal Amol covered exercise/tax liability with 709 shares, decreasing direct ownership by 8% to 7,796 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    3/3/26 4:22:14 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Leadership Updates

    Live Leadership Updates

    View All

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

    MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,

    5/21/25 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Appoints Heather Knight to Board of Directors

    MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for

    8/14/24 4:15:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Waters Corporation

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    11/12/24 11:54:03 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/14/24 9:37:22 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/13/24 5:17:31 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Financials

    Live finance-specific insights

    View All

    Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results

    Highlights Fourth Quarter 2025 Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currencyGrowth led by high single-digit constant currency growth in Pharma and Industrial end-markets, with broad-based growth across all regionsChemistry grew 12% in constant currency as new bioseparations products continued to experience significant customer demandInstruments grew 3% in constant currency, with high single-digit LC-MS growth partially offset by TA and transition to subscription model for EmpowerGAAP EPS of $3.77; non-GAAP EPS of $4.53 grew double digitsFull-Year 2025 Sales of $3,165 million grew 7% as reported and 7% in

    2/9/26 6:30:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business

    Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transaction MILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly voted to approve the issuance of shares of Waters common stock to shareholders of Becton, Dickinson and Company (NYSE:BDX) ("BD") in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters. 

    1/27/26 9:25:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Schedules Fourth Quarter 2025 Earnings Conference Call

    MILFORD, Mass., Jan. 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q4 2025 financial results conference call on Thursday, February 12th, 2026 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least March 12, 2026, at midnight Eastern Time. About Waters Corporation  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety o

    1/20/26 1:00:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials